A TP-sensitive K ϩ channels (K ATP channels) belong to a class of inwardly rectifying K ϩ channels that are activated by a decrease in the ATP͞ADP ratio (1-4). The resulting hyperpolarization lowers cell activity and energy consumption and thereby links metabolic state to excitability (3). Importantly, K ATP channels also play a role in the regulation of secretory events. A classic example is K ATP -channel-dependent regulation of insulin secretion from pancreatic beta cells (5, 6) . With normal extracellular levels of glucose, beta-cell K ATP channels are open; when glucose levels increase, ATP levels rise, leading to K ATPchannel closure, membrane depolarization, and consequent Ca 2ϩ -dependent insulin release (7) . The function of K ATP channels in the CNS is less well defined. These channels are widely expressed in brain, with high levels in nigrostriatal dopamine (DA) cells and striatum (8) (9) (10) (11) (12) (13) (14) . In contrast to pancreatic beta cells, however, K ATP channels in many brain cell types are normally closed. For example, in DA neurons of the substantia nigra pars compacta, K ATP channels do not contribute to resting membrane properties, although membrane hyperpolarization occurs when these channels are activated by selective openers or decreased levels of oxygen and͞or glucose (15) (16) (17) (18) (19) (20) . Consistent with these data, activation of K ATP channels by specific openers or by metabolic inhibition decreases the release of several neurotransmitters, including DA (21, 22) , ␥-aminobutyric acid (GABA) (15, (23) (24) (25) (26) , and glutamate (27) (28) (29) (30) (31) . Together, these data have suggested that brain K ATP channels may provide neuroprotection during metabolic stress. Significantly, however, these metabolically sensitive channels can be activated also under normal physiological conditions. For example, in the hypothalamus, K ATP channels in glucose-sensitive and -responsive cells contribute to the regulation of systemic glucose homeostasis (32) (33) (34) ; in the brainstem, these channels control the excitability of vagal neurons (35) and medullary respiratory cells (36) . Whether K ATP channels modulate CNS-transmitter release under nonpathological conditions and what factors regulate channel opening, however, have not been established.
We reported recently that glutamate inhibits DA release in the striatum by a pathway that involves H 2 O 2 generated downstream from the activation of glutamatergic ␣-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors (37) . The discovery of this inhibitory action of glutamate resolves a long-standing conundrum about how glutamate modulates DA release in striatum in the absence of ionotropic glutamate receptors on DA terminals (38, 39) . The mechanism of AMPA receptor-H 2 O 2 -dependent modulation is not yet known. Establishing this mechanism is important, however, because of the critical role of DA-glutamate interactions in movement control, cognitive processing, and the mediation of motivation and reward; correspondingly, DA-glutamate dysfunction has been implicated in Parkinson's disease (40, 41) , schizophrenia (42, 43) , and substance abuse (44, 45) .
Preliminary studies suggested that the mechanism of glutamate-H 2 O 2 -dependent inhibition of DA release might involve K ATP channels because the increase in DA release seen when AMPA receptors are blocked (and H 2 O 2 generation is suppressed) can be prevented by the sulfonylurea tolbutamide (37) . Consistent with this hypothesis, Krippeit-Drews et al. (46) have shown that exogenous H 2 O 2 can lead to the opening of tolbutamide-sensitive K ATP channels in pancreatic beta cells and thereby inhibit insulin release. On the other hand, it has been reported that tolbutamide can also inhibit K ϩ channels linked to dopaminergic D 2 receptors in both DA and non-DA cells (22, (47) (48) (49) . The experiments described here were designed to resolve whether K ATP channels or another K ϩ channel mediates glutamate-and GABA-dependent inhibition of DA release.
Materials and Methods
DA Recording in Striatal Slices. All animal handling procedures were in accordance with National Institutes of Health guidelines and were approved by the New York University School of Medicine Animal Care and Use Committee. Young adult guinea pigs (male, Hartley, 150-250 g) were deeply anesthetized with 40 mg⅐kg Ϫ1 pentobarbital (i.p.) and decapitated. Coronal brain slices containing striatum (400-m thickness) were prepared as described previously and then kept for at least 1 h in Hepesbuffered artificial cerebrospinal fluid (aCSF) before experimentation (50, 51) . After transfer to a submersion recording chamber at 32°C, slices were allowed a 30-min equilibration before stimulation; the superfusing aCSF contained (in mM): 124 NaCl, 3.7 KCl, 26 NaHCO 3 , 2.4 CaCl 2 , 1.3 MgSO 4 , 1.3 KH 2 PO 4 , and 10 glucose, equilibrated with 95% O 2 ͞5% CO 2 .
Fast-scan cyclic voltammetry was performed by a Millar Voltammeter (PD Systems International, West Molesey, U.K.); voltammetric procedures and data acquisition have been described (51) . Carbon-fiber microelectrodes were made from single 8-m carbon fibers; tip diameters were 2-4 m (MPB Electrodes, London). Electrodes were calibrated in the recording chamber at 32°C after each experiment, and sensitivity to DA was determined in all experimental media used (37, 51) . Release of DA was elicited in dorsolateral striatum by using a bipolar stimulating electrode on the slice surface; the carbon-fiber microelectrode was positioned between the poles, and the tip was inserted 50-100 m beneath the slice surface (50, 51) . The stimulus was a 10-Hz train of 30 pulses (pulse duration was 100 s; pulse amplitude was 0.4-0.6 mA). Release of DA under these conditions is Ca 2ϩ -dependent and can be blocked by tetrodotoxin (51) . Identification of released DA was based on characteristic DA voltammograms (Fig. 1B) . Our previous studies confirmed that the evoked response in striatum is free from interference from other electroactive substances, including 5-hydroxytryptamine (serotonin), the DA metabolite DOPAC (3,4-dihydroxyphenylacetic acid), and ascorbate (52).
Drug and Chemicals. Glibenclamide, (Ϫ)-sulpiride, 5-hydroxydecanoic acid (5-HD), mercaptosuccinic acid (MCS), 1-(4-aminophenyl)-4-methyl-7,8-methylenedioxy-5H-2,3-benzodiazepine hydrochloride (GYKI-52466), picrotoxin, and all components of aCSF and Hepes-aCSF were obtained from Sigma. Tertiapin was obtained from Peptide Institute (Osaka); diazoxide and cromakalim were obtained from Tocris Cookson (Ellisville, MO). All experimental solutions were made immediately before use. Stock solutions of glibenclamide were made in ethanol (0.02% final concentration in aCSF); diazoxide and cromakalim stock solutions were made in DMSO (0.01% final concentration in aCSF). Control data for these agents were obtained in vehicle; at the concentrations used, neither ethanol nor DMSO altered evoked DA release compared with that in aCSF alone.
Experimental Design and Statistical Analysis. Pharmacological inhibition of glutathione peroxidase by MCS inhibits H 2 O 2 metabolism and can thereby increase H 2 O 2 availability (53, 54). We have used MCS previously as a tool to reveal the role of endogenous H 2 O 2 generated during pulse-train stimulation in DA-release modulation (37, 55) . Evoked DA release in the presence of MCS is significantly lower than control release in aCSF alone; the specific involvement of H 2 O 2 was confirmed by the reversal of this release suppression by catalase in the continued presence of MCS (37) . Moreover, generation of modulatory H 2 O 2 requires AMPA-receptor activation: MCS has no effect on DA release when AMPA receptors were blocked with GYKI-52466. Conversely, modulation of DA release by GYKI-52466 or by the GABA type A (GABA A ) receptor antagonist picrotoxin is prevented by catalase, demonstrating that H 2 O 2 is required for DA-release regulation by endogenous glutamate and GABA (37) .
In the present experiments, therefore, we used either MCS (1 mM) or GYKI-52466 (50 M) (37) to screen the ability of specific K ϩ blockers and openers to alter H 2 O 2 -dependent modulation of DA release. Key findings were confirmed by testing an agent against MCS, GYKI-52466, and picrotoxin (100 M) (37) individually. In all experiments, the interval between stimulation trains was 10 min. Only slices with at least three consistent evoked increases in extracellular DA concentration ([DA] o ) under control conditions were used for these experiments; this criterion excluded Ϸ5% of slices tested. After consistent DA release was confirmed, a blocker or opener was superfused for 30-40 min, and continual recording of evoked [DA] o was performed; MCS, GYKI-52466, or picrotoxin was then applied in the continued presence of the test agent.
Data are given as mean Ϯ SEM (n ϭ number of slices) and illustrated as percentage of control. For each slice, the last three control records obtained before drug application were averaged and the mean peak [DA] o was taken as 100% for that slice. For studies in which the effect of a given K ϩ -channel agent was tested for efficacy against DA-release modulation by MCS, GYKI-52466, and picrotoxin, statistical comparisons were made by using pooled control and test agent data. In all experiments, differences in peak evoked [DA] o between conditions were assessed by using unpaired Student's t tests and were considered to be significant when P Ͻ 0.05. ), or the sulfonylurea, tolbutamide (46, 56) . In pilot studies, Ba 2ϩ (100 M) prevented the suppression of evoked DA release (10 Hz, 30 pulses) by exogenous H 2 O 2 (1.5 mM) and by MCS (1 mM) applied sequentially in a given slice (n ϭ 3; data not shown). These findings indicated a common mechanism involving K ϩ channels for both exogenous and endogenous H 2 O 2 . We found also that tolbutamide (200 M) prevented inhibition of DA release by endogenous H 2 O 2 in striatum (37).
Results

Glibenclamide Prevents
Here we tested the suggested involvement of K ATP channels by using a more potent K ATP -channel blocker, glibenclamide. Consistent with a role for K ATP channels, glibenclamide (3 M) (6, 57) caused a 60% increase in evoked [DA] o from a control level of 2.0 Ϯ 0.1 M (P Ͻ 0.01; n ϭ 5) (Fig. 1 A) . Identification and quantification of evoked DA release were made by comparing voltammograms obtained during local stimulation in striatum with voltammograms recorded during subsequent DA calibration (Fig. 1B) . In the continued presence of glibenclamide, the usual suppression of DA release in MCS was prevented completely (P Ͼ 0.05; n ϭ 5) (Fig. 1C) . Modulation of DA release by AMPA-and GABA A -receptor activation was also blocked: neither GYKI-52466 nor picrotoxin altered evoked [DA] o in the presence of glibenclamide (P Ͼ 0.05; n ϭ 5 for GYKI-52466 or picrotoxin) (Fig. 1C) . In paired controls, MCS caused a 40% decrease in evoked [DA] o , whereas GYKI-52466 induced a 100% increase in DA release and picrotoxin caused a 50% decrease (data not shown); these control responses were similar to those reported (37, 55) .
Lack of Involvement of D2 Receptors or G Protein-Activated K ؉
Channels. Several reports have suggested a G protein-coupled interaction between K ATP channels and D 2 receptors in the nigrostriatal pathway (22, 47, 48, 58) . Most relevant for the present studies, both tolbutamide and glibenclamide have been shown to inhibit D 2 -receptor-activated K ϩ channels and the resultant membrane hyperpolarization (47, 48) . We therefore examined whether such interactions might underlie the prevention of DA-release modulation by these sulfonylureas. The possible involvement of D 2 receptors was tested by using the specific D 2 receptor antagonist sulpiride (1 M) (41). Consistent with previous findings (51, 59), sulpiride caused a marked increase (80%) in maximum evoked [DA] o ( Fig. 2A) (P Ͻ 0.001; n ϭ 6). However, the D 2 -receptor blockade did not prevent the expected inhibition of DA release that accompanies glutathione peroxidase inhibition by MCS (P Ͻ 0.001, sulpiride ϩ MCS vs. sulpiride alone; n ϭ 6) (Fig. 2 A) .
We then tested the possible involvement of other G proteincoupled K ϩ channels by using tertiapin (10 nM to 1 M) (60, 61), which is a general inhibitor of G protein-activated inwardly rectifying K ϩ channels (62) . The efficacy of tertiapin at each concentration tested was indicated by an increase in evoked [DA] o . The lowest concentration (10 nM) produced an Ϸ50% increase in evoked [DA] o but did not alter the further increase in evoked [DA] o induced by GYKI-52466 (data not shown). A maximum effect of tertiapin was seen with 100 nM; no further increase was seen with 300 nM or 1 M. The mean increase in evoked [DA] o for pooled data for 100 nM to 1 M tertiapin was 62% (P Ͻ 0.001; n ϭ 7) (Fig. 2B) . Even with these supramaximal concentrations of tertiapin, the usual effect of AMPA-receptor blockade persisted (P Ͻ 0.001, tertiapin ϩ GYKI-52466 vs. tertiapin alone; n ϭ 7) (Fig. 2B) . Together, these data show that neither D 2 -receptor-linked K ϩ channels nor other G proteinactivated inwardly rectifying K ϩ channels contribute to the modulation of DA release by endogenously generated H 2 O 2 . They confirm also that the effects of glibenclamide and tolbutamide in this experimental paradigm are K ATP -channel specific.
H2O2-Dependent Inhibition of DA Release Does Not Involve Mitochondrial K ATP Channels. Glibenclamide and tolbutamide can inhibit mitochondrial K ATP (mitK ATP ) channels, as well as those in the plasma membrane (63, 64) . To distinguish the site of K ATPchannel activation by H 2 O 2 , we tested the efficacy of 5-HD, a selective inhibitor of mitK ATP -channel function (65) . Like the sulfonylureas, 5-HD (100 M) (66) caused an increase (43%) in peak [DA] o (P Ͻ 0.01; n ϭ 4) (Fig. 3) . However, 5-HD did not prevent the usual increase in DA release caused by blockade of AMPA receptors by GYKI-52466 (P Ͻ 0.001, 5-HD ϩ GYKI-52466 vs. 5-HD alone; n ϭ 4) (Fig. 3) , which demonstrated a lack of involvement of mitK ATP channels in glutamate-H 2 O 2 -dependent inhibition.
Effects of Selective KATP Channel Openers on DA Release. K ATP channels are multimeric proteins containing two distinct subunits, which are an inwardly rectifying pore-forming subunit (Kir6.1 or Kir6.2) and a sulfonylurea receptor subunit 1 or 2 (SUR1͞2) (7, (67) (68) (69) . In brain, most channels contain Kir6.2 (70, 71) . SUR1-and SUR2-based channels can be distinguished by their differential sensitivity to K ATP -channel openers; preferential selectivity of diazoxide corresponds to SUR1 and selectivity of cromakalim corresponds to SUR2 (72, 73) . We therefore compared the efficacy of these openers on evoked DA release. Activation of K ATP channels by either diazoxide-suppressed (30 M) (74) or cromakalim-suppressed (30 M) (72) DA release, with a 42% decrease in peak [DA] o in diazoxide (P Ͻ 0.01; n ϭ 5) and a 32% decrease in peak [DA] o in cromakalim (P Ͻ 0.01; n ϭ 5) (Fig. 4) . Diazoxide completely prevented the usual effects of MCS, GYKI-52466, and picrotoxin on DA release (Fig. 4 Upper; P Ͼ 0.05 vs. diazoxide alone for each agent; n ϭ 5 for each). In sharp contrast, cromakalim did not alter the expected effect of any of these agents (Fig. 4 Lower): inhibition of glutathione peroxidase by MCS in the presence of cromakalim resulted in a further decrease in evoked [DA] o (P Ͻ 0.05, cromakalim ϩ MCS vs. cromakalim alone; n ϭ 5). GYKI-52466 caused the usual increase in evoked [DA] o (P Ͻ 0.05; n ϭ 5), and PTX caused the usual decrease (P Ͻ 0.05; n ϭ 5). These data specifically implicate H 2 O 2 -sensitive SUR1-containing K ATP channels in the modulation of striatal DA release by glutamate and GABA.
Discussion
The data reported here demonstrate that K ATP channels can modulate CNS transmitter release as a response to fast synaptic transmission by glutamate and GABA. Additionally, these studies show that H 2 O 2 is the second messenger that mediates this response. Exogenous H 2 O 2 has been shown to lead to K ATPchannel opening in beta cells and subsequent inhibition of insulin release (36); however, a role for endogenous H 2 O 2 in K ATP -channel regulation has not been reported previously. The normally closed state of K ATP channels in the CNS and their known activation by deprivation of oxygen and͞or glucose have suggested that a primary function is to provide neuroprotection during ischemia or other brain injury (8, 17, 27, 29, 31, (75) (76) (77) . However, these channels also have significant roles in normal physiology, including maintenance of glucose homeostasis by glucose-sensing cells of the hypothalamus (32-34) and regulation of excitability in metabolically sensitive cells of the vagal and respiratory centers (35, 36) . The present studies reveal a regulatory function for K ATP channels that requires H 2 O 2 as a key signaling molecule.
Are D2 Receptors Involved? Our previous studies with tolbutamide suggested that sulfonylurea-sensitive K ϩ channels mediate AMPA-receptor-H 2 O 2 -dependent modulation of DA release (37) . This finding was confirmed by the present results with glibenclamide ( Fig. 1) . These data alone fall short of proving K ATP -channel involvement, however, because of the potential interaction between sulfonylureas and D 2 receptors, which activate G protein-coupled K ϩ channels (78, 79) . In the substantia nigra pars compacta, tolbutamide has been shown to reverse D 2 -autoreceptor-mediated inhibition of DA neurons (47) , and in the striatum, both tolbutamide and glibenclamide can antagonize D 2 -mediated inhibition in non-DA neurons (48) . These and other results have suggested a link between D 2 receptors and K ATP channels in which signal transduction is mediated by G proteins (22, (47) (48) (49) 58) , although such coupling is not seen under all experimental conditions (80, 81) . The H 2 O 2 -sensitive K ATP channels described in the present report appear to be distinct from striatal K ATP channels examined previously. In the studies of Lin et al. (48) , for example, tolbutamide was 10-to 100-fold more potent than glibenclamide in blocking D 2 -receptor-mediated inhibition in striatal neurons. This relative potency is opposite to that required for prevention of AMPAreceptor-H 2 O 2 -mediated inhibition of DA release: glibenclamide was effective at 3 M (Fig. 1) , whereas 200 M tolbutamide was required (37) .
Moreover, we found no evidence for the involvement of D 2 receptors or G protein coupling in the modulation of striatal DA release by H 2 O 2 -sensitive K ATP channels. Like tolbutamide or glibenclamide, the D 2 antagonist sulpiride caused a significant increase in evoked [DA] o ; unlike the sulfonylureas, however, sulpiride did not alter the usual decrease in DA release when H 2 O 2 availability was increased by MCS (Fig. 2 A) . Similarly, tertiapin, a G protein-activated, inwardly rectifying K ϩ -channel inhibitor, caused a significant increase in evoked [DA] o but had no effect AMPA-receptor-dependent modulation of DA release (Fig. 2B) . Thus, these data demonstrate the independence of H 2 O 2 -sensitive K ATP channels and D 2 -receptor-linked or other G protein-coupled K ϩ channels in striatum. Recent evidence suggests that endogenous H 2 O 2 can activate mitK ATP channels in cardiac myocytes during ischemic preconditioning (82) . A necessary experiment, therefore, was to assess the role of mitK ATP channels in glutamate-H 2 O 2 -dependent modulation of striatal DA release. This assessment required the use of a selective mitK ATP -channel blocker, 5-HD (65), because neither glibenclamide nor tolbutamide can distinguish between mitK ATP channels and those in plasma membranes (63, 64) . Interestingly, 5-HD alone caused an increase in evoked [DA] o ; this finding suggests some involvement of mitK ATP channels in DA-release regulation (Fig. 3) . One possible explanation for this increase is that 5-HD caused a decrease in mitochondrial production of reactive oxygen species, which can accompany a mitK ATP -channel blockade (83); mitochondrial respiration is a significant source of cellular reactive oxygen species, including H 2 O 2 (84) . Despite this effect of 5-HD under control conditions, this mitK ATP -channel blocker did not prevent a further increase in evoked [DA] o when AMPA receptors were blocked, demonstrating that mitK ATP channels are not involved in the dynamic modulation of DA release by H 2 O 2 .
Final confirmation that K ATP channels are required for DArelease modulation by H 2 O 2 , glutamate, and GABA was provided by the loss of efficacy of MCS, GYKI-52466, and picrotoxin when K ATP channels had already been opened by diazoxide (Fig. 4) . Together with the inability of SUR2-selective cromakalim to alter H 2 O 2 -dependent DA modulation by these agents, this result specifically implicates SUR1-based K ATP channels (71, 72) . These findings do not exclude other roles for SUR2-based channels in DA modulation because cromakalim, like diazoxide, did cause a significant decrease in control-evoked [DA] o (Fig. 4) . However, the data indicate that the K ATP channels targeted by AMPA-receptordependent H 2 O 2 in striatum contain SUR1 subunits. The question of whether the effect of H 2 O 2 is direct or mediated by additional pathways [e.g., by altering ATP levels as exogenous H 2 O 2 does in pancreatic beta cells (46) ] remains open. The most logical location for H 2 O 2 -sensitive K ATP channels to modulate striatal DA release is on the presynaptic membrane of DA release sites. Such localization is supported by the high expression of sulfonylurea binding sites in DA cells of the substantia nigra pars compacta (8, 10, 11, 13) , which project to dorsal striatum (85) . Moreover, a majority of K ATP channels in DA cells express Kir6.2 subunits combined with SUR1 rather than SUR2 subunits because of the greater metabolic sensitivity of SUR1-vs. SUR2-based channels (86) . The most likely site of AMPA-receptor-dependent H 2 O 2 generation, on the other hand, is in medium spiny neurons, given the absence of AMPA and GABA A receptors on DA terminals and the abundance of these receptors on spiny neurons (37) (38) (39) 87) . Although K ATP channels are also expressed in medium spiny neurons (88) , the present findings argue against significant involvement of those channels. We have already shown that activation of inhibitory GABA A receptors opposes AMPA-receptor-dependent H 2 O 2 generation and thereby increases DA release (37) . K ATP -channel opening in medium spiny neurons would be expected to have a similar effect by opposing AMPA-receptor-dependent excitation and H 2 O 2 generation. Thus, if K ATP channels in medium spiny neurons were the primary targets of H 2 O 2 , one would expect enhanced DA release in the presence of K ATP openers and suppressed DA release in the presence of K ATP -channel blockers. However, the opposite behaviors were observed (Figs. 1 and 4), consistent with direct presynaptic regulation of DA release. Together, these data support a model of striatal DArelease regulation (37) in which AMPA-receptor-dependent H 2 O 2 diffuses from postsynaptic sites in medium spiny neurons to inhibit DA release by activating H 2 O 2 -sensitive K ATP channels in presynaptic DA terminals.
Conclusions
The data reported here demonstrate a functional role for K ATP channels in the regulation of transmitter release in dorsal striatum. Moreover, they reveal that these channels are normally activated by H 2 O 2 generated downstream from AMPA-receptor activation and modulated by GABA A -receptor input. The specific K ATP channels involved are plasmalemmal SUR1-based channels, with probable location on DA axon terminals. Given that endogenous H 2 O 2 also inhibits synaptic DA release in ventral striatum (nucleus accumbens) and somatodendritic DA release in the substantia nigra pars compacta (55), we anticipate that K ATP channels will be shown to mediate H 2 O 2 -dependent modulation of DA release throughout motor and reward centers of the brain. The present findings should therefore help to clarify normal DA-glutamate interactions in these regions. Because DA-glutamate dysfunction has been implicated as a causal factor in Parkinson's disease, schizophrenia, and addiction (40) (41) (42) (43) (44) (45) 89) , these data may also suggest novel pathways through which such dysfunction could occur.
As noted above, K ATP channels are expressed abundantly in DA cells; the most metabolically sensitive of these channels are composed of SUR1 and Kir6.2 subunits (86) . The characteristics of DA-cell K ATP channels (e.g., whether they are G protein coupled and the extent to which they interact with D 2 receptors) are unresolved. The K ATP channels shown here to mediate inhibition of axonal DA release in striatum are sensitive to endogenous H 2 O 2 , are not G protein coupled, and are independent from D 2 receptors. Whether these are the defining characteristics of known K ATP channels expressed in DA cells or whether they describe a novel class of K ATP channel awaits further investigation.
